January 08, 2024

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

November 08, 2023

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

November 08, 2023

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

November 06, 2023

Revance to Participate in Upcoming Investor Conferences

November 01, 2023

Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 26, 2023

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

September 19, 2023

Revance Provides Corporate Update at Investor Day

August 22, 2023

Revance to Host Investor Day on September 19, 2023

August 14, 2023

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

August 08, 2023

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

August 01, 2023

Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

May 23, 2023

Revance to Participate in Upcoming Investor Conferences

May 09, 2023

Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update

May 02, 2023

Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 05, 2023

Revance to Participate in the Needham 22nd Annual Healthcare Conference

March 30, 2023

Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report

March 07, 2023

Revance to Participate in Upcoming Investor Conferences

February 28, 2023

Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

February 28, 2023

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

February 27, 2023

Revance to Participate in the 43rd Annual Cowen Healthcare Conference

February 23, 2023

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

February 21, 2023

Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

January 09, 2023

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

January 06, 2023

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

November 22, 2022

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

November 17, 2022

Nanostics Announces New Member of Board of Directors

November 09, 2022

Revance to Participate in the Stifel 2022 Healthcare Conference

November 08, 2022

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

November 04, 2022

Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment

November 01, 2022

Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 20, 2022

Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

October 17, 2022

Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer

October 10, 2022

Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

September 21, 2022

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

September 19, 2022

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

September 15, 2022

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

September 15, 2022

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 12, 2022

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

September 12, 2022

Revance Announces Proposed Public Offering of Common Stock

September 08, 2022

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

August 09, 2022

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

August 02, 2022

Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

July 27, 2022

Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference

April 21, 2022

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

March 28, 2022

Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

March 21, 2022

Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management

March 08, 2022

Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

February 28, 2022

Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

February 22, 2022

Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

January 18, 2022

Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA